Giant Study Boosts Januvia, Merck's $6 Billion Drug
Januvia, a widely used diabetes drug that generates $6 billion in annual sales for maker Merck, does not increase patients’ risk of being hospitalized for heart failure, a risk that did show up in clinical trials of competing drugs.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Matthew Herper Source Type: news
More News: Cardiology | Clinical Trials | Diabetes | Endocrinology | Heart | Heart Failure | Januvia | Merck | Pharmaceuticals | Study